BLCO on NYSE

Bausch & Lomb

Logo: Bausch & Lomb Inc, Public domain, via Wikimedia Commons4

Canadian eye health company

Bausch & Lomb (since 2010 stylized as Bausch + Lomb) is a Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

1853Founded1

Compare with The Cooper Companies, Alcon or National Vision Holdings, Inc., or pick any stock.

  • TickerBLCO on NYSE1
  • Industrypharmaceutical industry1
  • HeadquartersVaughan1
  • Founded inRochester1
  • Websitewww.bausch.com
  • Legal formjoint-stock company1
  • Business address520 Applewood Crescent, Vaughan, A6 L4K 4B45
  • Filer categoryLarge accelerated filer5
John Bausch and Henry Lomb, New York State Men Biographic Studies and Character Portraits (1910)
Photo: The Argus Company, Public domain, via Wikimedia Commons7

Bausch & Lomb (since 2010 stylized as Bausch + Lomb) is a Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

2.2%Operating margin8
-7.1%Net margin8
6.5%Revenue growth, 20258
-5.6%Return on equity8
0.78×Debt to equity8
-$66.0MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Device Products brought in 38% of the revenue Bausch & Lomb broke down this way in fiscal 2025.

  1. Device Products$1.9B838%up 7% from 2024
  2. Over the Counter Products$1.8B836%up 6% from 2024
  3. Pharmaceutical Products$1.1B821%up 12% from 2024
  4. Branded and Other Generic Products$243.0M85%down 14% from 2024
  5. Other Revenues$21.0M80%up 24% from 2024
  6. Product and Service, Other$21.0M80%up 24% from 2024
Products and services by year
Products and services202320242025
Device Products$1.6B$1.8B$1.9B
Over the Counter Products$1.6B$1.7B$1.8B
Pharmaceutical Products$618.0M$969.0M$1.1B
Branded and Other Generic Products$252.0M$281.0M$243.0M
Other Revenues$15.0M$17.0M$21.0M
Product and Service, Other$15.0M$17.0M$21.0M

Business segments

Vision Care brought in 57% of the revenue Bausch & Lomb broke down this way in fiscal 2025.

  1. Vision Care$2.9B857%up 7% from 2024
  2. Pharmaceuticals$1.3B825%up 6% from 2024
  3. Surgical$894.0M818%up 6% from 2024
Business segments by year
Business segments202320242025
Vision Care$2.5B$2.7B$2.9B
Pharmaceuticals$836.0M$1.2B$1.3B
Surgical$767.0M$843.0M$894.0M

Regions

United States and Puerto Rico brought in 51% of the revenue Bausch & Lomb broke down this way in fiscal 2025.

  1. United States and Puerto Rico$2.5B851%up 6% from 2024
  2. Other Countries$777.0M816%up 9% from 2024
  3. China$358.0M87%up 0% from 2024
  4. France$246.0M85%up 8% from 2024
  5. Japan$186.0M84%up 3% from 2024
  6. Germany$164.0M83%up 8% from 2024
  7. RU$148.0M83%up 23% from 2024
  8. United Kingdom$137.0M83%up 4% from 2024
  9. Canada$135.0M83%up 6% from 2024
  10. Italy$102.0M82%up 12% from 2024
  11. Spain$101.0M82%up 10% from 2024
  12. Mexico$75.0M82%up 0% from 2024
Regions by year
Regions202320242025
United States and Puerto Rico$1.9B$2.4B$2.5B
Other Countries$655.0M$712.0M$777.0M
China$344.0M$358.0M$358.0M
France$210.0M$227.0M$246.0M
Japan$187.0M$180.0M$186.0M
Germany$147.0M$152.0M$164.0M
RU$106.0M$120.0M$148.0M
United Kingdom$121.0M$132.0M$137.0M
Canada$110.0M$127.0M$135.0M
Italy$82.0M$91.0M$102.0M
Spain$85.0M$92.0M$101.0M
Mexico$68.0M$75.0M$75.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Selling, general and admin44¢$2.2B
  • Other costs56¢$2.8B
  • Income tax1¢$35.0M

Out of $5.1B in revenue.8 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending100¢$349.0M

Out of $283.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.8

Financial statements

Revenue910118$5.1B in 2025+50% since 2020
0$2.0B$4.0B$6.0B2020: $3.4B$3.4B20202021: $3.8B$3.8B2021+10%2022: $3.8B$3.8B2022+0%2023: $4.1B$4.1B2023+10%2024: $4.8B$4.8B2024+16%2025: $5.1B$5.1B2025+6%
Operating income910118$113.0M in 2025−57% since 2020
0$100.0M$200.0M$300.0M$400.0M2020: $260.0M$260.0M20202021: $329.0M$329.0M2021+27%2022: $207.0M$207.0M2022−37%2023: $130.0M$130.0M2023−37%2024: $162.0M$162.0M2024+25%2025: $113.0M$113.0M2025−30%
Net income910118-$360.0M in 2025+1900% since 2020
-$400.0M-$200.0M0$200.0M2020: -$18.0M-$18.0M20202021: $182.0M$182.0M20212022: $6.0M$6.0M2022−97%2023: -$260.0M-$260.0M20232024: -$317.0M-$317.0M2024+22%2025: -$360.0M-$360.0M2025+14%

Every line of the income statement in the latest annual report, as filed.8

Period ending2025-12-312024-12-312023-12-31
Total revenues$5.1B$4.8B$4.1B
Selling, general and administrative (Note 3)$2.2B$2.1B$1.7B
Research and development$371.0M$343.0M$324.0M
Amortization of intangible assets$258.0M$288.0M$240.0M
Other expense, net$75.0M$44.0M$74.0M
Total expenses$5.0B$4.6B$4.0B
Operating income$113.0M$162.0M$130.0M
Interest income$12.0M$15.0M$15.0M
Interest expense-$421.0M-$399.0M-$283.0M
Loss on extinguishment of debt-$6.0M$0$0
Foreign exchange and other-$15.0M-$12.0M-$28.0M
Loss before provision for income taxes-$317.0M-$234.0M-$166.0M
Provision for income taxes-$35.0M-$71.0M-$82.0M
Net loss-$352.0M-$305.0M-$248.0M
Net income attributable to noncontrolling interest-$8.0M-$12.0M-$12.0M
Net loss attributable to Bausch + Lomb Corporation-$360.0M-$317.0M-$260.0M
Basic loss per share attributable to Bausch + Lomb Corporation (in usd per share)-$1.02-$0.90-$0.74
Diluted loss per share attributable to Bausch + Lomb Corporation (in usd per share)-$1.02-$0.90-$0.74
Basic weighted-average common shares (in shares)353.8M shares351.8M shares350.5M shares
Diluted weighted-average common shares (in shares)353.8M shares351.8M shares350.5M shares

Compare Bausch & Lomb with another company

The story

Founded by Henry Lomb and John Jacob Bausch in 1853, in Rochester.1

Early years

In 1853, John Bausch and Henry Lomb, both German immigrants, established a small but ambitious workshop producing monocles in Rochester, New York. By 1861, their operation had expanded to manufacturing vulcanite rubber eyeglass frames and other precision vision products.

During the American Civil War, the Union blockade caused the price of gold and European horn to rise dramatically. This resulted in a growing demand for the Bausch + Lomb spectacles made from vulcanite.

In 1876, Ernst Gundlach joined the company as it began to manufacture microscopes. Later that year, the Bausch & Lomb Optical Company won a distinction at the Philadelphia Centennial Exposition. The company also produced photographic lenses (1883), spectacle lenses (1889), microtomes (1890), binoculars and telescopes (1893). From 1892 in cooperation with Zeiss in Germany, the company produced optical lenses. In this manner, at the end of the 19th century, the product range included eyeglasses, microscopes and binoculars, as well as projectors, camera lenses and camera diaphragms.

20th century

With the growth of the US army, under President Theodore Roosevelt and the buildup of the naval fleet, Bausch & Lomb received the commission, through the supplier Saegmuller, to manufacture high-precision lenses for optical measurement and founded a joint venture with Saegmuller. At the same time as this new expansion, a research department with five members was started to develop new products and improve old ones. A new alliance with the Zeiss company in Germany ensured competitive advantages for the three participants, Bausch & Lomb, Saegmuller and Zeiss, in terms of patent use and opening new markets. In 1902, William Bausch, the son of the founder, developed a process to create the desired lens shape directly by casting molten glass. Previously, the glass parts for the lenses had to be separated, ground and polished in a complicated process, and this brought significant savings in time and materials.

The company produced the first optical-quality glass in America during the early to mid-1900s. By the year 1903 the company began manufacturing microscopes, binoculars, and camera shutters.

The further development of the firm was affected by political events. Because of the World Wars and the consequent need for optical instruments such as field glasses, range finders, camera lenses, binocular telescopes, searchlight mirrors, torpedo tube sights, and periscopes, the product range could be considerably broadened. Until World War I, optical glass and the instruments made from it (including many military instruments) were often imported into most European and North American countries from Germany. The same was also true of chemical products and laboratory equipment. The outbreak of the war, with Germany's new enemy status, created a scramble to rapidly enhance the domestic industries. In 1933, Bausch + Lomb started to honor outstanding high school science students with the Bausch+Lomb Honorary Science Award. In the 1930s, military products represented 70% of total production. The Ray-Ban brand of sunglasses was developed for pilots in 1936.

At a time when the cinema was being superseded by television, Bausch & Lomb developed improved optics for the CinemaScope process, which popularized the film-based anamorphic format and led most cinemas to double the widths of their screens.

In 1965 Bausch & Lomb acquired the patent for the hydrogel contact lenses created by Czech scientists Otto Wichterle and Drahoslav Lím. In 1971, after three years of development work, two years for the medical approval by the United States Food and Drug Administration and an investment of three million USD, Bausch + Lomb launched contact lenses made of Poly-HEMA. In contrast to the contact lenses previously available, made of glass and Lucite (acrylic glass), the new lenses were softer. They were marketed under the brand name "Soflens".

Read the full text

In the 1970s, the company was a major producer of spectrophotometers for the dye and chemical business, such as the Spectronic 20.

A massive restructuring of the company began in the mid-1980s. What had been the core divisions, the production of lenses for various purposes, were sold off. The sunglasses division was continued as Ray-Ban and kept selling well due to effective product placement. By the planned acquisition of other firms, such as Polymer Technology Corporation and Dr. Mann Pharma, existing business areas such as contact lens production were strengthened and new ones were initiated.

In 1997, as a result of a series of company acquisitions, the division for the manufacture of surgical products was established. The Ray-Ban brand was sold in 1999 to the Italian Luxottica Group.

21st century

Since then, Bausch & Lomb has developed into a globally operating company which is one of the largest producers of contact lenses. As of 2022, about 12,900 employees in approximately 100 countries work for the firm.

Competitors in the international eye care products market are Johnson & Johnson, Allergan, Alcon, MSD-Chibret, CooperVision, Menicon Co., Hoya Corporation, EssilorLuxottica and Carl Zeiss Meditec.

In 2023, Bausch + Lomb Corp announced it would buy Xiidra from Novartis for $1.75 billion and pay additional $750 million in linked to future sales for Xiidra as well as two pipeline asset.

In 2025, Bausch + Lomb's subsidiaries closed an offering of $790.6 million.

From Wikipedia’s article on Bausch & Lomb, shared under CC BY-SA 4.0.6

Leadership

Who has led Bausch & Lomb, and when. Pick a name to see everywhere that person has worked.

Products and brands

In the last few years, several business areas in the Vision Care division have been developed in the framework of product diversification.

Vision care made $656 million during the first quarter of 2025, with revenua mainly coming from Daily SiHy lenses, Bausch + Lomb ULTRA®, over-the-counter dry eye products, LUMIFY, and eye vitamins.

On July 2, 2004, the company announced that it had licensed the intellectual property of Novartis.

From Wikipedia’s article on Bausch & Lomb, shared under CC BY-SA 4.0.6

Employees over time

  • 202212,9001
  • 201812,0001

Timeline

  1. 1853Founded Founded in Rochester1

Recent filings

  1. Oct 13, 20268-K
  2. Sep 28, 2026144
  3. Aug 14, 20263 PRIMARY DOCUMENT
  4. Aug 14, 20263 PRIMARY DOCUMENT
  5. Aug 14, 20264 PRIMARY DOCUMENT
  6. Aug 14, 20263 PRIMARY DOCUMENT
  7. Aug 14, 20264 PRIMARY DOCUMENT
  8. Aug 14, 20263 PRIMARY DOCUMENT
  9. Aug 14, 20264 PRIMARY DOCUMENT
  10. Aug 12, 20268-K/A
  11. Aug 12, 20264 PRIMARY DOCUMENT
  12. Aug 11, 2026144/A
  13. Aug 10, 2026144
  14. Aug 10, 20264
  15. Aug 7, 20264 PRIMARY DOCUMENT

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2